Anti-obesity Drugs Market Report

Europe Anti-obesity Drugs Market Size, Status and Forecast 2014-2026

  • POSTDATE：Jan 13, 2020
  • PAGES：185
  • REPORT CODE：GMM433745
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The Anti-obesity Drugs market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 5.7% during the forecast period. Focusing on the Europe market, this report analyzes the specific consumption structure, such as types and end users. In order to present the status of the circulation of this product in different Europe countries, this report covers top export and import countries to confirm the potential markets. Leading countries such as Germany, UK, France, Italy, Spain, Poland, Russia, Switzerland, Turkey, Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden), Benelux (Belgium, Netherlands, and Luxembourg), Baltic States (Estonia, Latvia, and Lithuania) and other countries, the market status and consumption potential of these countries are covered in the research, providing valuable opinions of strategic adjustments for existing groups and new entrants.

    The Snapshot of Europe Anti-obesity Drugs Market Segmentations:

    By Player:

    • Pfizer

    • Eisai

    • Roche

    • GlaxoSmithKline

    • Arena Pharmaceuticals

    • Novo Nordisk

    • Merck

    • Amylin

    • Vivus

    • Orexigen Therapeutics

    • Boehringer Ingelheim

    • Alizyme

    By Type:

    • Peripherally Acting Anti-obesity Drugs

    • Centrally Acting Anti-obesity Drugs

    By End-User:

    • Kids

    • Adults

    By Region:

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Poland

    • Russia

    • Switzerland

    • Turkey

    • Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden)

      • Denmark

      • Finland

      • Norway

      • Sweden

      • Iceland

    • Benelux (Belgium, Netherlands, and Luxembourg)

      • Belgium

      • Netherlands

      • Luxembourg

    • Baltic States (Estonia, Latvia, and Lithuania)

      • Estonia

      • Latvia

      • Lithuania

  • Table of Contents

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Anti-obesity Drugs Market

    • 1.3 Market Segment by Type

    • 1.3.1 Europe Anti-obesity Drugs Market Size and Growth Rate of Peripherally Acting Anti-obesity Drugs from 2014 to 2026

    • 1.3.2 Europe Anti-obesity Drugs Market Size and Growth Rate of Centrally Acting Anti-obesity Drugs from 2014 to 2026

    • 1.4 Market Segment by Application

    • 1.4.1 Europe Anti-obesity Drugs Market Size and Growth Rate of Kids from 2014 to 2026

    • 1.4.2 Europe Anti-obesity Drugs Market Size and Growth Rate of Adults from 2014 to 2026

    • 1.5 Market Segment by Regions

      • 1.5.1 Germany Anti-obesity Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.2 UK Anti-obesity Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.3 France Anti-obesity Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.4 Italy Anti-obesity Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.5 Spain Anti-obesity Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.6 Poland Anti-obesity Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.7 Russia Anti-obesity Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.8 Switzerland Anti-obesity Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.9 Turkey Anti-obesity Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Anti-obesity Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.11 Benelux (Belgium, Netherlands, and Luxembourg) Anti-obesity Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.12 Baltic States (Estonia, Latvia, and Lithuania) Anti-obesity Drugs Market Size and Growth Rate from 2014 to 2026

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    3 Segmentation of Anti-obesity Drugs Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Venders

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Anti-obesity Drugs by Major Types

      • 3.4.1 Market Size and Growth Rate of Peripherally Acting Anti-obesity Drugs

      • 3.4.2 Market Size and Growth Rate of Centrally Acting Anti-obesity Drugs

    4 Segmentation of Anti-obesity Drugs Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Anti-obesity Drugs by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Anti-obesity Drugs for Kids

      • 4.4.2 Market Size and Growth Rate of Anti-obesity Drugs for Adults

    5 Market Analysis by Major Regions

    • 5.1 Europe Anti-obesity Drugs Production Analysis by Top Regions

    • 5.2 Europe Anti-obesity Drugs Consumption Analysis by Top Regions

    • 5.3 Europe Anti-obesity Drugs Production, Import, Consumption and Export Analysis by Regions

      • 5.3.1 Germany Anti-obesity Drugs Production, Import, Consumption and Export Analysis

      • 5.3.2 UK Anti-obesity Drugs Production, Import, Consumption and Export Analysis

      • 5.3.3 France Anti-obesity Drugs Production, Import, Consumption and Export Analysis

      • 5.3.4 Italy Anti-obesity Drugs Production, Import, Consumption and Export Analysis

      • 5.3.5 Spain Anti-obesity Drugs Production, Import, Consumption and Export Analysis

      • 5.3.6 Poland Anti-obesity Drugs Production, Import, Consumption and Export Analysis

      • 5.3.7 Russia Anti-obesity Drugs Production, Import, Consumption and Export Analysis

      • 5.3.8 Switzerland Anti-obesity Drugs Production, Import, Consumption and Export Analysis

      • 5.3.9 Turkey Anti-obesity Drugs Production, Import, Consumption and Export Analysis

      • 5.3.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Anti-obesity Drugs Production, Import, Consumption and Export Analysis

      • 5.3.11 Benelux (Belgium, Netherlands, and Luxembourg) Anti-obesity Drugs Production, Import, Consumption and Export Analysis

      • 5.3.12 Baltic States (Estonia, Latvia, and Lithuania) Anti-obesity Drugs Production, Import, Consumption and Export Analysis

    6 Product Circulation of Anti-obesity Drugs Market among Top Countries

    • 6.1 Top 5 Export Countries in Anti-obesity Drugs Market from 2014 to 2019

      • 6.1.1 Top 5 Export Countries’ Export Value Analysis in Anti-obesity Drugs Market from 2014 to 2019

      • 6.1.2 Top 5 Export Countries’ Export Volume Analysis in Anti-obesity Drugs Market from 2014 to 2019

    • 6.2 Top 5 Import Countries in Anti-obesity Drugs Market from 2014 to 2019

      • 6.2.1 Top 5 Import Countries’ Import Value Analysis in Anti-obesity Drugs Market from 2014 to 2019

      • 6.2.2 Top 5 Import Countries’ Import Volume Analysis in Anti-obesity Drugs Market from 2014 to 2019

    • 6.3 Emerging Top 3 Export Countries Analysis

    • 6.4 Emerging Top 3 Import Countries Analysis

    7. Germany Anti-obesity Drugs Landscape Analysis

    • 7.1 Germany Anti-obesity Drugs Landscape Analysis by Major Types

    • 7.2 Germany Anti-obesity Drugs Landscape Analysis by Major End-Users

    8. UK Anti-obesity Drugs Landscape Analysis

    • 8.1 UK Anti-obesity Drugs Landscape Analysis by Major Types

    • 8.2 UK Anti-obesity Drugs Landscape Analysis by Major End-Users

    9. France Anti-obesity Drugs Landscape Analysis

    • 9.1 France Anti-obesity Drugs Landscape Analysis by Major Types

    • 9.2 France Anti-obesity Drugs Landscape Analysis by Major End-Users

    10. Italy Anti-obesity Drugs Landscape Analysis

    • 10.1 Italy Anti-obesity Drugs Landscape Analysis by Major Types

    • 10.2 Italy Anti-obesity Drugs Landscape Analysis by Major End-Users

    11. Spain Anti-obesity Drugs Landscape Analysis

    • 11.1 Spain Anti-obesity Drugs Landscape Analysis by Major Types

    • 11.2 Spain Anti-obesity Drugs Landscape Analysis by Major End-Users

    12. Poland Anti-obesity Drugs Landscape Analysis

    • 12.1 Poland Anti-obesity Drugs Landscape Analysis by Major Types

    • 12.2 Poland Anti-obesity Drugs Landscape Analysis by Major End-Users

    13. Russia Anti-obesity Drugs Landscape Analysis

    • 13.1 Russia Anti-obesity Drugs Landscape Analysis by Major Types

    • 13.2 Russia Anti-obesity Drugs Landscape Analysis by Major End-Users

    14. Switzerland Anti-obesity Drugs Landscape Analysis

    • 14.1 Switzerland Anti-obesity Drugs Landscape Analysis by Major Types

    • 14.2 Switzerland Anti-obesity Drugs Landscape Analysis by Major End-Users

    15. Turkey Anti-obesity Drugs Landscape Analysis

    • 15.1 Turkey Anti-obesity Drugs Landscape Analysis by Major Types

    • 15.2 Turkey Anti-obesity Drugs Landscape Analysis by Major End-Users

    16. Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Anti-obesity Drugs Landscape Analysis

    • 16.1 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Anti-obesity Drugs Landscape Analysis by Major Types

    • 16.2 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Anti-obesity Drugs Landscape Analysis by Major End-Users

    • 16.3 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Anti-obesity Drugs Landscape Analysis by Top Countries

      • 16.3.1 Denmark Anti-obesity Drugs Market Volume and Growth Rate

      • 16.3.2 Finland Anti-obesity Drugs Market Volume and Growth Rate

      • 16.3.3 Norway Anti-obesity Drugs Market Volume and Growth Rate

      • 16.3.4 Sweden Anti-obesity Drugs Market Volume and Growth Rate

      • 16.3.6 Iceland Anti-obesity Drugs Market Volume and Growth Rate

    17 Benelux (Belgium, Netherlands, and Luxembourg) Anti-obesity Drugs Landscape Analysis

    • 17.1 Benelux (Belgium, Netherlands, and Luxembourg) Anti-obesity Drugs Landscape Analysis by Major Types

    • 17.2 Benelux (Belgium, Netherlands, and Luxembourg) Anti-obesity Drugs Landscape Analysis by Major End-Users

    • 17.3 Benelux (Belgium, Netherlands, and Luxembourg) Anti-obesity Drugs Landscape Analysis by Top Countries

      • 17.3.1 Belgium Anti-obesity Drugs Market Volume and Growth Rate

      • 17.3.2 Netherlands Anti-obesity Drugs Market Volume and Growth Rate

      • 17.3.3 Luxembourg Anti-obesity Drugs Market Volume and Growth Rate

    18 Baltic States (Estonia, Latvia, and Lithuania) Anti-obesity Drugs Landscape Analysis

    • 18.1 Baltic States (Estonia, Latvia, and Lithuania) Anti-obesity Drugs Landscape Analysis by Major Types

    • 18.2 Baltic States (Estonia, Latvia, and Lithuania) Anti-obesity Drugs Landscape Analysis by Major End-Users

    • 18.3 Baltic States (Estonia, Latvia, and Lithuania) Anti-obesity Drugs Landscape Analysis by Top Countries

      • 18.3.1 Estonia Anti-obesity Drugs Market Volume and Growth Rate

      • 18.3.2 Latvia Anti-obesity Drugs Market Volume and Growth Rate

      • 18.3.3 Lithuania Anti-obesity Drugs Market Volume and Growth Rate

    19 Major Players Profiles

    • 19.1 Pfizer

      • 19.1.1 Pfizer Company Profile and Development Status

      • 19.1.2 Market Performance

      • 19.1.3 Product and Service Introduction

    • 19.2 Eisai

      • 19.2.1 Eisai Company Profile and Development Status

      • 19.2.2 Market Performance

      • 19.2.3 Product and Service Introduction

    • 19.3 Roche

      • 19.3.1 Roche Company Profile and Development Status

      • 19.3.2 Market Performance

      • 19.3.3 Product and Service Introduction

    • 19.4 GlaxoSmithKline

      • 19.4.1 GlaxoSmithKline Company Profile and Development Status

      • 19.4.2 Market Performance

      • 19.4.3 Product and Service Introduction

    • 19.5 Arena Pharmaceuticals

      • 19.5.1 Arena Pharmaceuticals Company Profile and Development Status

      • 19.5.2 Market Performance

      • 19.5.3 Product and Service Introduction

    • 19.6 Novo Nordisk

      • 19.6.1 Novo Nordisk Company Profile and Development Status

      • 19.6.2 Market Performance

      • 19.6.3 Product and Service Introduction

    • 19.7 Merck

      • 19.7.1 Merck Company Profile and Development Status

      • 19.7.2 Market Performance

      • 19.7.3 Product and Service Introduction

    • 19.8 Amylin

      • 19.8.1 Amylin Company Profile and Development Status

      • 19.8.2 Market Performance

      • 19.8.3 Product and Service Introduction

    • 19.9 Vivus

      • 19.9.1 Vivus Company Profile and Development Status

      • 19.9.2 Market Performance

      • 19.9.3 Product and Service Introduction

    • 19.10 Orexigen Therapeutics

      • 19.10.1 Orexigen Therapeutics Company Profile and Development Status

      • 19.10.2 Market Performance

      • 19.10.3 Product and Service Introduction

    • 19.11 Boehringer Ingelheim

      • 19.11.1 Boehringer Ingelheim Company Profile and Development Status

      • 19.11.2 Market Performance

      • 19.11.3 Product and Service Introduction

    • 19.12 Alizyme

      • 19.12.1 Alizyme Company Profile and Development Status

      • 19.12.2 Market Performance

      • 19.12.3 Product and Service Introduction

    The List of Tables and Figures (Totals 66 Figures and 128 Tables)

    • Figure Product Picture

    • Figure Europe Anti-obesity Drugs Market Size and Growth Rate of Peripherally Acting Anti-obesity Drugs from 2014 to 2026

    • Figure Europe Anti-obesity Drugs Market Size and Growth Rate of Centrally Acting Anti-obesity Drugs from 2014 to 2026

    • Figure Europe Anti-obesity Drugs Market Size and Growth Rate of Kids from 2014 to 2026

    • Figure Europe Anti-obesity Drugs Market Size and Growth Rate of Adults from 2014 to 2026

    • Figure Germany Anti-obesity Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure UK Anti-obesity Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure France Anti-obesity Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Italy Anti-obesity Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Spain Anti-obesity Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Poland Anti-obesity Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Russia Anti-obesity Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Switzerland Anti-obesity Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Turkey Anti-obesity Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Canada Anti-obesity Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Mexico Anti-obesity Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Anti-obesity Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Denmark Anti-obesity Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Finland Anti-obesity Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Norway Anti-obesity Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Sweden Anti-obesity Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Iceland Anti-obesity Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Benelux (Belgium, Netherlands, and Luxembourg) Anti-obesity Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Belgium Anti-obesity Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Netherlands Anti-obesity Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Luxembourg Anti-obesity Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Baltic States (Estonia, Latvia, and Lithuania) Anti-obesity Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Estonia Anti-obesity Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Latvia Anti-obesity Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Lithuania Anti-obesity Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Development Trends and Industry Dynamics of Anti-obesity Drugs Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 6 Players from 2014 to 2019

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of Anti-obesity Drugs

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Anti-obesity Drugs by Different Types from 2014 to 2026

    • Table Consumption Share of Anti-obesity Drugs by Different Types from 2014 to 2026

    • Figure Market Size and Growth Rate of Peripherally Acting Anti-obesity Drugs

    • Figure Market Size and Growth Rate of Centrally Acting Anti-obesity Drugs

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of Anti-obesity Drugs by Different End-Users from 2014 to 2026

    • Table Consumption Share of Anti-obesity Drugs by Different End-Users from 2014 to 2026

    • Figure Market Size and Growth Rate of Kids

    • Figure Market Size and Growth Rate of Adults

    • Table Europe Anti-obesity Drugs Production by Major Regions

    • Table Europe Anti-obesity Drugs Production Share by Major Regions

    • Figure Europe Anti-obesity Drugs Production Share by Major Countries and Regions in 2014

    • Table Europe Anti-obesity Drugs Consumption by Major Regions

    • Table Europe Anti-obesity Drugs Consumption Share by Major Regions

    • Table Germany Anti-obesity Drugs Production, Import, Consumption and Export Analysis

    • Table UK Anti-obesity Drugs Production, Import, Consumption and Export Analysis

    • Table France Anti-obesity Drugs Production, Import, Consumption and Export Analysis

    • Table Italy Anti-obesity Drugs Production, Import, Consumption and Export Analysis

    • Table Spain Anti-obesity Drugs Production, Import, Consumption and Export Analysis

    • Table Poland Anti-obesity Drugs Production, Import, Consumption and Export Analysis

    • Table Russia Anti-obesity Drugs Production, Import, Consumption and Export Analysis

    • Table Switzerland Anti-obesity Drugs Production, Import, Consumption and Export Analysis

    • Table Turkey Anti-obesity Drugs Production, Import, Consumption and Export Analysis

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Anti-obesity Drugs Production, Import, Consumption and Export Analysis

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Anti-obesity Drugs Production, Import, Consumption and Export Analysis

    • Table Baltic States (Estonia, Latvia, and Lithuania) Anti-obesity Drugs Production, Import, Consumption and Export Analysis

    • Table Top 5 Export Countries' Export Value Analysis in Anti-obesity Drugs Market from 2014 to 2019

    • Table Top 5 Export Countries' Export Volume Analysis in Anti-obesity Drugs Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Value Analysis in Anti-obesity Drugs Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Volume Analysis in Anti-obesity Drugs Market from 2014 to 2019

    • Figure Emerging Top 3 Export Countries Analysis

    • Figure Emerging Top 3 Import Countries Analysis

    • Table Germany Anti-obesity Drugs Consumption by Types from 2014 to 2026

    • Table Germany Anti-obesity Drugs Consumption Share by Types from 2014 to 2026

    • Table Germany Anti-obesity Drugs Consumption by End-Users from 2014 to 2026

    • Table Germany Anti-obesity Drugs Consumption Share by End-Users from 2014 to 2026

    • Table UK Anti-obesity Drugs Consumption by Types from 2014 to 2026

    • Table UK Anti-obesity Drugs Consumption Share by Types from 2014 to 2026

    • Table UK Anti-obesity Drugs Consumption by End-Users from 2014 to 2026

    • Table UK Anti-obesity Drugs Consumption Share by End-Users from 2014 to 2026

    • Table France Anti-obesity Drugs Consumption by Types from 2014 to 2026

    • Table France Anti-obesity Drugs Consumption Share by Types from 2014 to 2026

    • Table France Anti-obesity Drugs Consumption by End-Users from 2014 to 2026

    • Table France Anti-obesity Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Italy Anti-obesity Drugs Consumption by Types from 2014 to 2026

    • Table Italy Anti-obesity Drugs Consumption Share by Types from 2014 to 2026

    • Table Italy Anti-obesity Drugs Consumption by End-Users from 2014 to 2026

    • Table Italy Anti-obesity Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Spain Anti-obesity Drugs Consumption by Types from 2014 to 2026

    • Table Spain Anti-obesity Drugs Consumption Share by Types from 2014 to 2026

    • Table Spain Anti-obesity Drugs Consumption by End-Users from 2014 to 2026

    • Table Spain Anti-obesity Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Poland Anti-obesity Drugs Consumption by Types from 2014 to 2026

    • Table Poland Anti-obesity Drugs Consumption Share by Types from 2014 to 2026

    • Table Poland Anti-obesity Drugs Consumption by End-Users from 2014 to 2026

    • Table Poland Anti-obesity Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Russia Anti-obesity Drugs Consumption by Types from 2014 to 2026

    • Table Russia Anti-obesity Drugs Consumption Share by Types from 2014 to 2026

    • Table Russia Anti-obesity Drugs Consumption by End-Users from 2014 to 2026

    • Table Russia Anti-obesity Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Switzerland Anti-obesity Drugs Consumption by Types from 2014 to 2026

    • Table Switzerland Anti-obesity Drugs Consumption Share by Types from 2014 to 2026

    • Table Switzerland Anti-obesity Drugs Consumption by End-Users from 2014 to 2026

    • Table Switzerland Anti-obesity Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Turkey Anti-obesity Drugs Consumption by Types from 2014 to 2026

    • Table Turkey Anti-obesity Drugs Consumption Share by Types from 2014 to 2026

    • Table Turkey Anti-obesity Drugs Consumption by End-Users from 2014 to 2026

    • Table Turkey Anti-obesity Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Anti-obesity Drugs Consumption by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Anti-obesity Drugs Consumption Share by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Anti-obesity Drugs Consumption by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Anti-obesity Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Anti-obesity Drugs Consumption by Major Countries from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Anti-obesity Drugs Consumption Share by Major Countries from 2014 to 2026

    • Figure Denmark Anti-obesity Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Finland Anti-obesity Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Norway Anti-obesity Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Sweden Anti-obesity Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Iceland Anti-obesity Drugs Market Volume and Growth Rate from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Anti-obesity Drugs Consumption by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Anti-obesity Drugs Consumption Share by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Anti-obesity Drugs Consumption by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Anti-obesity Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Anti-obesity Drugs Consumption by Major Countries from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Anti-obesity Drugs Consumption Share by Major Countries from 2014 to 2026

    • Figure Belgium Anti-obesity Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Netherlands Anti-obesity Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Luxembourg Anti-obesity Drugs Market Volume and Growth Rate from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Anti-obesity Drugs Consumption by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Anti-obesity Drugs Consumption Share by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Anti-obesity Drugs Consumption by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Anti-obesity Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Anti-obesity Drugs Consumption by Major Countries from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Anti-obesity Drugs Consumption Share by Major Countries from 2014 to 2026

    • Figure Estonia Anti-obesity Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Latvia Anti-obesity Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Lithuania Countries Anti-obesity Drugs Market Volume and Growth Rate from 2014 to 2026

    • Table Company Profile and Development Status of Pfizer

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Pfizer

    • Figure Sales and Growth Rate Analysis of Pfizer

    • Figure Revenue and Market Share Analysis of Pfizer

    • Table Product and Service Introduction of Pfizer

    • Table Company Profile and Development Status of Eisai

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Eisai

    • Figure Sales and Growth Rate Analysis of Eisai

    • Figure Revenue and Market Share Analysis of Eisai

    • Table Product and Service Introduction of Eisai

    • Table Company Profile and Development Status of Roche

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Roche

    • Figure Sales and Growth Rate Analysis of Roche

    • Figure Revenue and Market Share Analysis of Roche

    • Table Product and Service Introduction of Roche

    • Table Company Profile and Development Status of GlaxoSmithKline

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of GlaxoSmithKline

    • Figure Sales and Growth Rate Analysis of GlaxoSmithKline

    • Figure Revenue and Market Share Analysis of GlaxoSmithKline

    • Table Product and Service Introduction of GlaxoSmithKline

    • Table Company Profile and Development Status of Arena Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Arena Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Arena Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Arena Pharmaceuticals

    • Table Product and Service Introduction of Arena Pharmaceuticals

    • Table Company Profile and Development Status of Novo Nordisk

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Novo Nordisk

    • Figure Sales and Growth Rate Analysis of Novo Nordisk

    • Figure Revenue and Market Share Analysis of Novo Nordisk

    • Table Product and Service Introduction of Novo Nordisk

    • Table Company Profile and Development Status of Merck

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Merck

    • Figure Sales and Growth Rate Analysis of Merck

    • Figure Revenue and Market Share Analysis of Merck

    • Table Product and Service Introduction of Merck

    • Table Company Profile and Development Status of Amylin

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Amylin

    • Figure Sales and Growth Rate Analysis of Amylin

    • Figure Revenue and Market Share Analysis of Amylin

    • Table Product and Service Introduction of Amylin

    • Table Company Profile and Development Status of Vivus

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Vivus

    • Figure Sales and Growth Rate Analysis of Vivus

    • Figure Revenue and Market Share Analysis of Vivus

    • Table Product and Service Introduction of Vivus

    • Table Company Profile and Development Status of Orexigen Therapeutics

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Orexigen Therapeutics

    • Figure Sales and Growth Rate Analysis of Orexigen Therapeutics

    • Figure Revenue and Market Share Analysis of Orexigen Therapeutics

    • Table Product and Service Introduction of Orexigen Therapeutics

    • Table Company Profile and Development Status of Boehringer Ingelheim

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Boehringer Ingelheim

    • Figure Sales and Growth Rate Analysis of Boehringer Ingelheim

    • Figure Revenue and Market Share Analysis of Boehringer Ingelheim

    • Table Product and Service Introduction of Boehringer Ingelheim

    • Table Company Profile and Development Status of Alizyme

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Alizyme

    • Figure Sales and Growth Rate Analysis of Alizyme

    • Figure Revenue and Market Share Analysis of Alizyme

    • Table Product and Service Introduction of Alizyme

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US